• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Zydus Cadila gets final US FDA nod for Pindolol tabs

expressbpdAugust 23, 2017

Tag: FDA , Zydus Cadila , Pindolol tabs

Zydus Cadila has received final approval from the US health regulator to market Pindolol tablets, used for treatment of hypertension.

The company has received approval from the US Food and Drug Administration (US FDA) to market the drug in the strengths of 5 mg and 10 mg, Zydus Cadila said in a BSE filing.

Pindolol belongs to a class of beta-blockers and is used to treat hypertension. The company said it will manufacture the drug at the groups manufacturing facility at the Pharma SEZ in Ahmedabad.

Previous:DRL out-licenses DFD-06 to Encore Dermatology

Next:Indian patent office grants patent to Pfizer for Prevnar 13

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Zydus Cadila gets final US FDA nod for Pindolol tabs | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Deltamine (FDA)

Deltamine (FDA)
Tobramycin base( FDA)

Tobramycin base( FDA)
Vecuronium (FDA)

Vecuronium (FDA)
Ramantadine( FDA)

Ramantadine( FDA)
High quality Stability Chamber(FS/CFS Series:FDA)

High quality Stability Chamber(FS/CFS Series:FDA)
HFHA(m-6FDAP)

HFHA(m-6FDAP)
Ribavirin (FDA)

Ribavirin (FDA)
Vitamine B12 (FDA)

Vitamine B12 (FDA)
Fluorouracil deoxyriboside( FDA)

Fluorouracil deoxyriboside( FDA)
Daunomycin HCL( FDA)

Daunomycin HCL( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service